Google Chrome
Safari
Firefox
Edge
Search
Press Release / Mar 18, 2025
Hovione’s new campus in Seixal enters final stage of construction. Set to open in mid-2027
Investment in Hovione Tejo will expand industrial capacity and strengthen the company’s global leadership in spray drying and other advanced pharmaceutical manufacturing technologies.
Press Release / Sep 20, 2019
Hovione announces successful end-of-phase 2 meeting with the FDA and outlines phase 3 program for minocycline topical gel
Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.
News / Jul 23, 2021
Hovione signs the COP26 manifest to stop climate changes
BCSD Portugal, 23 July 2021
Dispersome®
Make your drug soluble with Dispersome® technology. Dispersome® is a solubility enhancement technology that relies on an innovative and naturally occurring excipient to develop amorphous solid dispersions with high drug loading and high bioavailability.
Press Release / Sep 19, 2024
Hovione and iBET Announce the Establishment of ViSync® Technologies: A Venture in Cell and Gene Therapy Solutions
Commitment to partnership and joint innovation for cell and gene therapies
Press Clipping / Nov 12, 2018
How Hovione grew from a basement lab to a global pharmaceutical services company
C&EN, November 12, 2018
Press Clipping / Jun 21, 2021
Hovione meets increased demand during Covid
Irish Examiner, 21 june 2021